| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 11 | | | |
| | | | 24 | | | |
| | | | 25 | | | |
| | | | 26 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 29 | | | |
| | | | 30 | | | |
| | | | 30 | | | |
| | | | 30 | | | |
| | | | 31 | | | |
| | | | 31 | | | |
| | | | 32 | | | |
| | | | 32 | | | |
| | | | 33 | | | |
| | | | 34 | | | |
| | | | 35 | | | |
| | | | 36 | | | |
| | | | 36 | | | |
| | | | 36 | | | |
| | | | 37 | | | |
| | | | 37 | | | |
| | | | 56 | | | |
| | | | 61 | | | |
| | | | 70 | | | |
| | | | 73 | | | |
| | | | 74 | | | |
| | | | 74 | | | |
| | | | 74 | | | |
| | | | 76 | | | |
| | | | 76 | | | |
| | | | 77 | | | |
| | | | 77 | | | |
| | | | 77 | | |
| | |
Page
|
| |||
| | | | 77 | | | |
| | | | 78 | | | |
| | | | 78 | | | |
| | | | 78 | | | |
| | | | 79 | | | |
| | | | 80 | | | |
| | | | 80 | | | |
| | | | 82 | | | |
| | | | 84 | | | |
| | | | 85 | | | |
| | | | 88 | | | |
| | | | 88 | | | |
| | | | 90 | | | |
| | | | 92 | | | |
| | | | 94 | | | |
| | | | 95 | | | |
| | | | 97 | | | |
| | | | 97 | | | |
| | | | 99 | | | |
| | | | 101 | | | |
| | | | 102 | | | |
| | | | 102 | | | |
| | | | 102 | | | |
| | | | 102 | | | |
| | | | 103 | | | |
| | | | 110 | | | |
| | | | 113 | | | |
| | | | 119 | | | |
| | | | 122 | | | |
| | | | 123 | | | |
| | | | 124 | | | |
| | | | A-1 | | | |
| | | | B-1 | | |
Proposal
|
| |
Required Vote
|
| |
Effects of Certain Actions
|
|
Amedisys Proposal 1:
Amedisys Merger Proposal |
| | Approval requires the affirmative vote of the holders of a majority of all outstanding shares of Amedisys Common Stock entitled to vote thereon at the Amedisys Special Meeting | | | The failure to vote, the failure to instruct your brokerage firm, bank, dealer or other similar organization, trustee, or nominee to vote shares held in “street name” on the Amedisys Merger Proposal, an abstention from voting, or a broker | |
Proposal
|
| |
Required Vote
|
| |
Effects of Certain Actions
|
|
| | | | | | non-vote, if any, will have the same effect as a vote “AGAINST” the Amedisys Merger Proposal. | |
Amedisys Proposal 2: Amedisys Compensation Proposal | | | Approval requires the affirmative vote of a majority of the shares of Amedisys Common Stock present or represented by proxy at the Amedisys Special Meeting and entitled to vote thereon | | | Any shares not present or represented by proxy (including due to the failure of an Amedisys stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions with respect to any proposals at the Amedisys Special Meeting to such bank, broker or other nominee) will have no effect on the outcome of the Amedisys Compensation Proposal, provided that a quorum is otherwise present. An abstention by any shares present or represented by proxy on the Amedisys Compensation Proposal will have the same effect as a vote “AGAINST” the Amedisys Compensation Proposal. Broker non-votes, if any, will have no effect on the Amedisys Compensation Proposal | |
Amedisys Proposal 3: Amedisys Adjournment Proposal
|
| | Approval requires the affirmative vote of a majority of the shares of Amedisys Common Stock present or represented by proxy at the Amedisys Special Meeting and entitled to vote thereon | | | Any shares not present or represented by proxy (including due to the failure of an Amedisys stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions with respect to any proposals at the Amedisys Special Meeting to such bank, broker or other nominee) will have no effect on the outcome of the Amedisys Adjournment Proposal. An abstention by any shares present or represented by proxy on the Amedisys Adjournment Proposal will have the same effect as a vote “AGAINST” the Amedisys Adjournment Proposal. Broker non-votes, if any, will have no effect on the Amedisys Adjournment Proposal. | |
|
June 23, 2023 Closing Amedisys Share Price
|
| | | $ | 91.21 | | |
|
May 2, 2023 Closing Amedisys Share Price
|
| | | $ | 77.26 | | |
|
Per Share Merger Consideration
|
| | | $ | 101.00 | | |
| | |
Reference Range
for Amedisys Valuation |
| |||||||||
| | |
Low
|
| |
High
|
| ||||||
Financial Analyses | | | | ||||||||||
Discounted Cash Flow Analysis
|
| | | $ | 63.75 | | | | | $ | 103.25 | | |
Selected Precedent M&A Transactions
|
| | | $ | 71.00 | | | | | $ | 108.25 | | |
Selected Publicly Traded Companies Analyses: | | | | | | | | | | | | | |
2023E PF Adj. EBITDA
|
| | | $ | 77.00 | | | | | $ | 99.00 | | |
2024E PF Adj. EBITDA
|
| | | $ | 75.50 | | | | | $ | 90.25 | | |
For Informational Reference Purposes | | | | | | | | | | | | | |
May 2, 2023 Analyst Price Targets
|
| | | $ | 72.00 | | | | | $ | 130.00 | | |
June 23, 2023 Analyst Price Targets
|
| | | $ | 73.00 | | | | | $ | 115.00 | | |
52 Week High/Low Stock Prices
|
| | | $ | 69.37 | | | | | $ | 131.32 | | |
Announcement Date
|
| |
Acquiror
|
| |
Target
|
| |
Multiple of Transaction Equity
Value to LTM EBITDA (excluding non-controlling interest) |
|
Apr-22 | | | Clayton, Dubilier & Rice LLC | | | Kindred at Home | | |
10.6x
|
|
Mar-22 | | | UnitedHealth Group Incorporated | | | LHC Group, Inc. | | |
22.7x(1)
|
|
Dec-21 | | | Aveanna Healthcare | | | Comfort Care Home Health | | |
13.8x
|
|
Apr-21 | | | Humana Inc. | | |
Kindred Healthcare, Inc.
|
| |
12.5x(2)
|
|
Feb-21 | | | BrightSpring Health Services | | | Abode Healthcare | | |
15.5x
|
|
Oct-20 | | | H.I.G. Capital | | | St. Croix Hospice | | |
15.5x(3)
|
|
Oct-20 | | | Thomas H. Lee | | | Care Hospice | | |
15.0x(4)
|
|
Apr-20 | | | Amedisys, Inc. | | | AseraCare Hospice | | |
12.4x(5)
|
|
Oct-19 | | | TowerBrook Capital Partners L.P. / Ascension Health | | | Compassus | | |
11.8x(3)
|
|
Oct-18 | | | Amedisys, Inc. | | | Compassionate Care Hospice Group, Inc. | | |
10.7x
|
|
Apr-18 | | | Humana Inc. / TPG Capital / Welsh, Carson, Anderson & Stowe | | | Curo Health Services | | |
14.0x(6)
|
|
Nov-17 | | | LHC Group, Inc. | | | Almost Family, Inc. | | |
15.7x
|
|
Nov-14 | | |
HealthSouth Corporation
|
| | EHHI Holdings, Inc. | | |
10.6x(7)
|
|
Oct-14 | | |
Kindred Healthcare, Inc.
|
| | Gentiva Health Services, Inc. | | |
11.1x
|
|
Sep-13 | | | Gentiva Health Services, Inc. | | | Harden Healthcare Holdings, Inc. | | |
11.1x
|
|
Statistical Summary | | | | | | | | | | |
25th Percentile | | | | | | | | |
11.1x
|
|
Median | | | | | | | | |
12.5x
|
|
Mean | | | | | | | | |
13.5x
|
|
75th Percentile | | | | | | | | |
15.5x
|
|
| | |
Enterprise Value /
CY 2023E Adj. EBITDA |
| |
Enterprise Value /
CY 2024E Adj. EBITDA |
| ||||||
Unaffected Amedisys(1) | | | | | | | | | | | | | |
Amedisys-Provided Financial Information
|
| | | | 12.0x | | | | | | 11.7x | | |
Wall Street Equity Research Consensus Estimates
|
| | | | 12.8x | | | | | | 11.4x | | |
Other Home and Community Based Services Providers(2) | | | | | | | | | | | | | |
Addus Homecare Corporation
|
| | | | 15.2x | | | | | | 13.9x | | |
Aveanna Healthcare Holdings Inc.
|
| | | | 15.8x | | | | | | 14.2x | | |
Chemed Corporation
|
| | | | 18.5x | | | | | | 17.1x | | |
Enhabit, Inc.
|
| | | | 10.2x | | | | | | 9.7x | | |
ModivCare, Inc.
|
| | | | 7.4x | | | | | | 6.6x | | |
Statistical Summary for Other Home and Community Based Services Providers
|
| | | | | | | | | | | | |
Median
|
| | | | 15.2x | | | | | | 13.9x | | |
| | |
For Fiscal Year Ending December 31,
|
| |||||||||||||||||||||||||||
(dollars in millions)
|
| |
2023E
|
| |
2024E
|
| |
2025E
|
| |
2026E
|
| |
2027E
|
| |||||||||||||||
Revenue
|
| | | $ | 2,291 | | | | | $ | 2,481 | | | | | $ | 2,759 | | | | | $ | 3,157 | | | | | $ | 3,576 | | |
Adjusted EBITDA(2)
|
| | | $ | 239 | | | | | $ | 249 | | | | | $ | 272 | | | | | $ | 295 | | | | | $ | 318 | | |
EBIT(3) | | | | $ | 216 | | | | | $ | 232 | | | | | $ | 254 | | | | | $ | 278 | | | | | $ | 300 | | |
NOPAT(4) | | | | $ | 158 | | | | | $ | 169 | | | | | $ | 185 | | | | | $ | 203 | | | | | $ | 219 | | |
Free Cash Flow(5)
|
| | | $ | 159 | | | | | $ | 187 | | | | | $ | 180 | | | | | $ | 183 | | | | | $ | 199 | | |
| | |
For Fiscal Year Ending December 31,
|
| |||||||||||||||||||||||||||
(dollars in millions)
|
| |
Q2-Q4
2023E |
| |
2024E
|
| |
2025E
|
| |
2026E
|
| |
2027E
|
| |||||||||||||||
Revenue
|
| | | $ | 1,729 | | | | | $ | 2,435 | | | | | $ | 2,628 | | | | | $ | 2,845 | | | | | $ | 3,086 | | |
Adjusted EBITDA(2)
|
| | | $ | 187 | | | | | $ | 249 | | | | | $ | 272 | | | | | $ | 295 | | | | | $ | 318 | | |
EBIT(3) | | | | $ | 170 | | | | | $ | 232 | | | | | $ | 254 | | | | | $ | 278 | | | | | $ | 300 | | |
NOPAT(4) | | | | $ | 124 | | | | | $ | 169 | | | | | $ | 185 | | | | | $ | 203 | | | | | $ | 219 | | |
Free Cash Flow(5)
|
| | | $ | 147 | | | | | $ | 163 | | | | | $ | 172 | | | | | $ | 185 | | | | | $ | 198 | | |
Directors
|
| |
Total Shares
of Amedisys Common Stock (#) |
| |
Total
Estimated Value ($) |
| ||||||
Vickie L. Capps(1)
|
| | | | 6,450 | | | | | | 651,450 | | |
Molly J. Coye(1)
|
| | | | 5,450 | | | | | | 550,450 | | |
Julie D. Klapstein(1)
|
| | | | 12,663 | | | | | | 1,278,963 | | |
Teresa L. Kline(1)
|
| | | | 6,450 | | | | | | 651,450 | | |
Bruce D. Perkins(1)
|
| | | | 20,729 | | | | | | 2,093,629 | | |
Jeffrey A. Rideout(1)
|
| | | | 5,967 | | | | | | 602,667 | | |
Ivanetta Davis Samuels(1)
|
| | | | 4,232 | | | | | | 427,432 | | |
Executive Officers | | | | | | | | | | | | | |
Richard Ashworth
|
| | | | — | | | | | | — | | |
Paul Kusserow(2)
|
| | | | 516,979 | | | | | | 52,214,879 | | |
Scott B. Ginn(3)
|
| | | | 35,058 | | | | | | 3,540,858 | | |
Nicholas Muscato(4)
|
| | | | 2,884 | | | | | | 291,284 | | |
Michael P. North(5)
|
| | | | 4,704 | | | | | | 475,104 | | |
Denise Bohnert(6)
|
| | | | 10,504 | | | | | | 1,060,904 | | |
Christopher T. Gerard
|
| | | | 41,898 | | | | | | 4,231,698 | | |
David L. Kemmerly
|
| | | | 16,336 | | | | | | 1,649,936 | | |
Adam Holton
|
| | | | — | | | | | | — | | |
Named Executive Officer
|
| |
Cash
($)(1) |
| |
Equity
($)(2) |
| |
Other
($)(3) |
| |
Total
($) |
| ||||||||||||
Richard Ashworth
|
| | | | 6,000,000 | | | | | | 17,717,753 | | | | | | — | | | | | | 23,717,753 | | |
Paul Kusserow(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Scott B. Ginn
|
| | | | 2,700,000 | | | | | | 6,418,488 | | | | | | — | | | | | | 9,118,488 | | |
Nicholas Muscato
|
| | | | 1,400,000 | | | | | | 1,743,848 | | | | | | 250,000 | | | | | | 3,393,848 | | |
Michael P. North
|
| | | | 1,487,500 | | | | | | 1,239,597 | | | | | | — | | | | | | 2,727,097 | | |
Denise Bohnert
|
| | | | 1,400,000 | | | | | | 932,515 | | | | | | 150,000 | | | | | | 2,482,515 | | |
Christopher T. Gerard(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
David L. Kemmerly(6)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Named Executive Officer
|
| |
Base
Salary ($) |
| |
Bonus
($) |
| |
Cash
Severance Multiplier |
| |
Total
($) |
| ||||||||||||
Richard Ashworth
|
| | | | 1,000,000 | | | | | | 1,000,000 | | | | | | 3.0 | | | | | | 6,000,000 | | |
Paul Kusserow
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Scott B. Ginn
|
| | | | 675,000 | | | | | | 675,000 | | | | | | 2.0 | | | | | | 2,700,000 | | |
Nicholas Muscato
|
| | | | 400,000 | | | | | | 300,000 | | | | | | 2.0 | | | | | | 1,400,000 | | |
Michael P. North
|
| | | | 425,000 | | | | | | 318,750 | | | | | | 2.0 | | | | | | 1,487,500 | | |
Denise Bohnert
|
| | | | 400,000 | | | | | | 300,000 | | | | | | 2.0 | | | | | | 1,400,000 | | |
Christopher T. Gerard
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
David L. Kemmerly
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Named Executive Officer
|
| |
Unvested
Amedisys RSU Awards ($) |
| |
Unvested
Amedisys PSU Awards ($) |
| |
Unvested
Amedisys Option Awards ($) |
| |
Total
($) |
| ||||||||||||
Richard Ashworth
|
| | | | 7,513,592 | | | | | | 9,490,162 | | | | | | 713,999 | | | | | | 17,717,753 | | |
Paul Kusserow
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Scott B. Ginn
|
| | | | 5,386,532 | | | | | | 952,329 | | | | | | 79,627 | | | | | | 6,418,488 | | |
Nicholas Muscato
|
| | | | 1,409,051 | | | | | | 308,252 | | | | | | 26,545 | | | | | | 1,743,848 | | |
Michael P. North
|
| | | | 701,344 | | | | | | 498,435 | | | | | | 39,818 | | | | | | 1,239,597 | | |
Denise Bohnert
|
| | | | 580,043 | | | | | | 325,927 | | | | | | 26,545 | | | | | | 932,515 | | |
Christopher T. Gerard
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
David L. Kemmerly
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name of Beneficial Owner(1)
|
| |
Number of Shares
of Amedisys Common Stock |
| |
Percent of
Amedisys Common Stock(1) |
| ||||||
5% Stockholders | | | | | | | | | | | | | |
BlackRock, Inc.(2)
|
| | | | 4,106,566 | | | | | | 12.6% | | |
Wellington Management Group LLP(3)
|
| | | | 2,802,831 | | | | | | 8.6% | | |
The Vanguard Group, Inc.(4)
|
| | | | 3,128,416 | | | | | | 9.6% | | |
Ameriprise Financial, Inc.(5)
|
| | | | 1,100,719 | | | | | | 3.4% | | |
Deerfield Management, L.P.(6)
|
| | | | 1,794,000 | | | | | | 5.5% | | |
Executive Officers and Directors | | | | | | | | | | | | | |
Richard Ashworth
|
| | | | — | | | | | | — | | |
Vickie L. Capps(7)
|
| | | | 6,450 | | | | | | * | | |
Molly J. Coye, MD(7)
|
| | | | 5,450 | | | | | | * | | |
Julie D. Klapstein(7)
|
| | | | 12,663 | | | | | | * | | |
Teresa L. Kline(7)
|
| | | | 6,450 | | | | | | * | | |
Bruce D. Perkins(7)
|
| | | | 20,729 | | | | | | * | | |
Jeffrey A. Rideout, MD(7)
|
| | | | 5,967 | | | | | | * | | |
Ivanetta Davis Samuels(7)
|
| | | | 4,232 | | | | | | * | | |
Paul B. Kusserow(8)
|
| | | | 516,979 | | | | | | 1.6% | | |
Scott G. Ginn(9)
|
| | | | 35,058 | | | | | | * | | |
Nicholas Muscato(10)
|
| | | | 2,884 | | | | | | * | | |
Michael P. North(11)
|
| | | | 4,704 | | | | | | * | | |
Denise Bohnert(12)
|
| | | | 10,504 | | | | | | * | | |
Christopher T. Gerard(13)
|
| | | | 41,898 | | | | | | * | | |
David L. Kemmerly(14)
|
| | | | 16,336 | | | | | | * | | |
Adam Holton
|
| | | | — | | | | | | — | | |
All Executive Officers and Directors as a Group (16 persons)
|
| | | | 690,304 | | | | | | 2.12% | | |
| | |
Page
|
| |||
| | | | A-1 | | | |
| | | | A-1 | | | |
| | | | A-1 | | | |
| | | | A-2 | | | |
| | | | A-2 | | | |
| | | | A-2 | | | |
| | | | A-2 | | | |
| | | | A-2 | | | |
| | | | A-2 | | | |
| | | | A-5 | | | |
| | | | A-7 | | | |
| | | | A-7 | | | |
| | | | A-8 | | | |
| | | | A-8 | | | |
| | | | A-25 | | | |
| | | | A-27 | | | |
| | | | A-27 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-36 | | | |
| | | | A-36 | | | |
| | | | A-39 | | | |
| | | | A-40 | | | |
| | | | A-40 | | | |
| | | | A-40 | | | |
| | | | A-41 | | | |
| | | | A-41 | | | |
| | | | A-43 | | | |
| | | | A-43 | | | |
| | | | A-43 | | | |
| | | | A-44 | | | |
| | | | A-44 | | | |
| | | | A-44 | | | |
| | | | A-44 | | | |
| | | | A-45 | | | |
| | | | A-45 | | | |
| | | | A-45 | | |
| | |
Page
|
| |||
| | | | A-46 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-49 | | | |
| | | | A-49 | | | |
| | | | A-49 | | | |
| | | | A-50 | | | |
| | | | A-57 | | | |
| | | | A-57 | | | |
| | | | A-57 | | | |
| | | | A-58 | | | |
| | | | A-58 | | | |
| | | | A-58 | | | |
| | | | A-58 | | | |
| | | | A-58 | | | |
| | | | A-58 | | | |
| | | | A-59 | | | |
Exhibit | | | |||||
Exhibit A — Form of Certificate of Incorporation of the Surviving Corporation | | | | | | | |
Exhibit B — Merger Sub Written Consent | | | | | | | |
Term
|
| |
Section
|
|
2018 Plan | | | 9.3(a) | |
Action | | | 4.1(k) | |
affiliate | | | 9.3(b) | |
Agreement | | | Preamble | |
Amedisys | | | Preamble | |
Amedisys 401(k) Plan | | | 6.9(h) | |
Amedisys Alternative Transaction | | | 5.2(a) | |
Amedisys Balance Sheet | | | 4.1(e)(iii) | |
Amedisys Benefit Plan | | | 9.3(d) | |
Amedisys Book-Entry Share | | | 3.2(c) | |
Amedisys Certificate | | | 3.2(c) | |
Amedisys Common Stock | | | 4.1(c)(i) | |
Amedisys Disclosure Letter | | | 4.1 | |
Amedisys Equity Awards | | | 3.1(b)(v) | |
Amedisys Equity Awards Capitalization Table | | | 4.1(c)(iii) | |
Amedisys ESPP | | | 9.3(e) | |
Amedisys Filed SEC Documents | | | 4.1 | |
Amedisys Financial Advisor | | | 4.1(u) | |
Amedisys Foreign Plan | | | 4.1(l)(viii) | |
Amedisys Healthcare Professional | | | 4.1(h)(v) | |
Amedisys Intervening Event | | | 5.2(d) | |
Amedisys Material Contracts | | | 4.1(q)(xiv) | |
Amedisys Material Leased Real Property | | | 4.1(s)(ii) | |
Amedisys Material Real Property Lease | | | 4.1(s)(ii) | |
Amedisys Option | | | 3.1(b)(iii) | |
Amedisys Owned IP | | | 4.1(o) | |
Amedisys Permits | | | 4.1(g) | |
Amedisys Preferred Stock | | | 4.1(c)(i) | |
Amedisys Provider JVs | | | 9.3(f) | |
Amedisys PSU Award | | | 3.1(b)(ii) | |
Amedisys Recommendation Change | | | 5.2(b) | |
Amedisys Registered IP | | | 4.1(o) | |
Amedisys RSU Award | | | 3.1(b)(i) | |
Amedisys SEC Documents | | | 4.1(e)(i) | |
Amedisys Stock Plans | | | 9.3(g) | |
Amedisys Stockholder Approval | | | 4.1(t) | |
Amedisys Stockholders Meeting | | | 6.1(b) | |
Amedisys Superior Proposal | | | 5.2(a) | |
Amedisys Termination Fee | | | 8.2(b) | |
Amedisys Third Party | | | 5.2(a) | |
Anti-Corruption Laws | | | 9.3(c) | |
Term
|
| |
Section
|
|
Antitrust Laws | | | 4.1(b)(iii) | |
Applicable Laws | | | 4.1(g) | |
Bonus | | | 6.9(f) | |
Bonus Plans | | | 6.9(f) | |
Burdensome Condition | | | 9.3(h) | |
business day | | | 9.3(i) | |
Bylaws | | | 2.1(a) | |
Certificate of Merger | | | 1.3 | |
Change | | | 9.3(hh) | |
Closing | | | 1.2 | |
Closing Date | | | 1.2 | |
Closing Fiscal Year | | | 6.9(f) | |
COBRA | | | 4.1(l)(ii) | |
Code | | | 9.3(j) | |
Confidentiality Agreement | | | 9.3(k) | |
Continuation Period | | | 6.9(a) | |
Continuing Employee | | | 6.9(a) | |
control | | | 9.3(b) | |
COVID-19 | | | 9.3(l) | |
COVID-19 Measures | | | 9.3(m) | |
D&O Indemnified Parties | | | 6.4(b) | |
D&O Insurance | | | 6.4(c) | |
DGCL | | | 1.1 | |
Director RSU | | | 3.1(b)(iv) | |
Dissenting Shares | | | 9.3(n) | |
Dissenting Stockholders | | | 9.3(o) | |
Double-Trigger Protection | | | 9.3(p) | |
DTC | | | 9.3(q) | |
Effective Time | | | 1.3 | |
Enforceability Exceptions | | | 4.1(b)(i) | |
Environmental Laws | | | 9.3(r) | |
Environmental Permits | | | 4.1(r) | |
Equity Award Exchange Ratio | | | 9.3(s) | |
Equity Securities | | | 9.3(t) | |
ERISA | | | 9.3(u) | |
ERISA Affiliate | | | 9.3(v) | |
Exchange Act | | | 4.1(b)(iii) | |
Exchange Fund | | | 3.2(a) | |
Existing Indemnified Parties | | | 6.4(a) | |
Ex-Im Laws | | | 9.3(w) | |
GAAP | | | 4.1(e)(ii) | |
Governmental Entity | | | 4.1(b)(iii) | |
Governmental Health Program | | | 9.3(x) | |
Term
|
| |
Section
|
|
Harmful Code | | | 9.3(y) | |
Hazardous Materials | | | 9.3(z) | |
Healthcare Laws | | | 9.3(aa) | |
Healthcare Permits | | | 9.3(bb) | |
HIPAA | | | 9.3(cc) | |
HSR Act | | | 4.1(b)(iii) | |
Intellectual Property | | | 9.3(dd) | |
IRS | | | 4.1(l)(i) | |
IT Assets | | | 9.3(ee) | |
knowledge | | | 9.3(ff) | |
Labor Agreement | | | 9.3(gg) | |
Liens | | | 4.1(b)(ii) | |
Material Adverse Effect | | | 9.3(hh) | |
Maximum Premium | | | 6.4(c) | |
Measurement Date | | | 4.1(c)(i) | |
Merger | | | 1.1 | |
Merger Consideration | | | 3.1(a)(i) | |
Merger Sub | | | Preamble | |
Merger Sub Stockholder Approval | | | 4.2(e) | |
Merger Sub Written Consent | | | 4.2(e) | |
Multiemployer Plan | | | 9.3(ii) | |
NASDAQ | | | 6.1(b) | |
OPCH | | | Preamble | |
OPCH Agreement | | | Preamble | |
OPCH Agreement Termination Fee | | | Preamble | |
OPCH Agreement Termination Fee Refund | | | 8.2(d) | |
OPCH Merger Sub | | | Preamble | |
OPCH Termination Agreement | | | Preamble | |
Open Source Software | | | 9.3(jj) | |
Order | | | 9.3(kk) | |
Outside Counsel Only Material, | | | 6.3(b) | |
Outside Date | | | 8.1(b)(i) | |
Owned Amedisys Software | | | 4.1(o) | |
Parent | | | Preamble | |
Parent Filed SEC Documents | | | 4.2 | |
Parent Common Stock | | | 9.3(ll) | |
Parent Material Adverse Effect | | | 4.2(a) | |
Parent Trading Price | | | 9.3(mm) | |
Paying Agent | | | 3.2(a) | |
Paying Agent Agreement | | | 3.2(a) | |
Payor | | | 9.3(nn) | |
PCI DSS | | | 9.3(oo) | |
Per Share Merger Consideration | | | 9.3(pp) | |
Term
|
| |
Section
|
|
Permits | | | 4.1(g) | |
Permitted Confidentiality Agreement | | | 5.2(a) | |
Permitted Liens | | | 9.3(qq) | |
person | | | 9.3(rr) | |
Personal Data | | | 9.3(ss) | |
Potential Purchasers | | | 6.3(e) | |
Potential Sale Transaction | | | 6.3(e) | |
Privacy and Security Requirements | | | 9.3(tt) | |
Privacy Contracts | | | 9.3(uu) | |
Privacy Laws | | | 9.3(vv) | |
Privacy Policies | | | 9.3(ww) | |
Process | | | 9.3(xx) | |
Processing | | | 9.3(xx) | |
Proxy Statement | | | 4.1(b)(iii) | |
PTO Policy | | | 6.9(e) | |
Qualifying Event | | | 9.3(zz) | |
Referral Recipient | | | 4.1(h)(ix) | |
Referral Source | | | 4.1(h)(ix) | |
Regulatory Break Fee | | | 8.2(c) | |
Release | | | 9.3(yy) | |
Replacement Plans | | | 6.9(d) | |
Representatives | | | 9.3(aaa) | |
Sanctioned Person | | | 9.3(bbb) | |
Sanctions | | | 9.3(ccc) | |
Sarbanes-Oxley Act | | | 4.1(e)(i) | |
SEC | | | 3.1(b)(vi) | |
Securities Act | | | 4.1(e)(i) | |
Security Breach | | | 9.3(ddd) | |
Stimulus Funds | | | 9.3(fff) | |
subsidiary | | | 9.3(eee) | |
Surviving Corporation | | | 1.1 | |
Tail Policy | | | 6.4(c) | |
Tax Return | | | 9.3(ggg) | |
Taxes | | | 9.3(hhh) | |
Taxing Authority | | | 9.3(iii) | |
Termination Fee Amount | | | 8.2(b)(iii) | |
Transaction Litigation | | | 6.11 | |
WARN Act | | | 4.1(m)(ii) | |
Willful Breach | | | 9.3(jjj) | |
| | | | UNITEDHEALTH GROUP INCORPORATED | |
| | | |
By:
Name:
Title: |
|
|
|
| |
Guggenheim Securities, LLC
330 Madison Avenue New York, New York 10017 GuggenheimPartners.com |
|